Considerations For How Biomarker-Driven Stratification of Depressive Subtypes Will Be Viewed in the Eyes of the Regulators
Time: 4:00 pm
day: Day Two PM
Details:
- Evaluating the availability of validated or un-validated biomarkers in depression
- Deciphering the road to regulatory acceptance of a biomarker-identified population
- Navigating challenges of implementing robust biomarker criteria in the real world
- Discussing the pathway to commercialization for a precision therapy for mental health
